Hims prepares for peptides launch, Wall Street cautious on prospects this year

Hims & Hers Health plans to offer certain legally available peptides in 2026, but investors and analysts are not expecting peptide sales to meaningfully lift revenue this year, Reuters reported after the company’s quarterly results. CEO Andrew Dudum said Hims by year-end will sell peptides already legal for manufacturing, including NAD+, sermorelin and glutathione. Wall Street views the impact as limited because NAD+ is already available. The company is also running stability and validation testing for BPC-157, amid FDA review. Analysts note many peptides are bought through grey markets, complicating demand estimates. FDA “full and final rulemaking” could take about a year.